Phase 4 Type 2 Diabetes Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been diagnosed with type 2 diabetes according to Chinese clinical guidelines (2020 edition)
• People aged 18 to 75 years old (inclusive), of any gender
• People with a Body Mass Index (BMI) of 20 or above — BMI is a measure calculated from height and weight
• People who have been taking metformin (at a dose of 1000mg or more per day), with or without one other diabetes tablet (but not an SGLT-2 inhibitor or an oral GLP-1 medication), for at least 8 weeks before the screening visit, and whose blood sugar remains poorly controlled — specifically, a blood sugar marker called HbA1c must be between 7.5% and 11.0% as measured by the central lab
• People who are willing to take part in the study and have signed a consent form

Who may not be able to join:

• People who have type 1 diabetes, or any other specific type of diabetes other than type 2
• People who experienced a serious diabetes-related emergency (such as diabetic ketoacidosis, hyperosmolar state, or lactic acidosis) within the 6 months before screening
• People who have used a GLP-1 or SGLT-2 type diabetes medication within the 12 weeks before screening, or who have previously tried and stopped one of these medications because it did not work well enough
• People who received insulin treatment in the week before screening
• People who have a history of pancreatitis (inflammation of the pancreas), whether past or current, or who have very high triglyceride (blood fat) levels at screening (above 5.7 mmol/L)
• People whose liver is not functioning well at screening — specifically, if certain liver test results (ALT, AST, or total bilirubin) are significantly above the normal range
• People whose kidneys are not functioning well enough at screening — assessed using a standard kidney function calculation (eGFR at or below 45 mL/min/1.73m²) or elevated creatinine levels
• People who have a personal or family history of a specific type of thyroid cancer (medullary thyroid cancer), or a condition called Multiple Endocrine Neoplasia type 2 (MEN2)
• People who are currently pregnant, breastfeeding, or planning to become pregnant during the study period
• People who have had an allergic reaction or known sensitivity to metformin, dapagliflozin, liraglutide, or any ingredients in these study medications
• People who have taken part in another clinical drug trial within the 3 months before screening
• People who, in the opinion of the trial doctor, are unable to follow the study plan, or who have other serious physical or mental health conditions that could affect the study results or their safety (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.